Request Demo
Recent blog posts
Latest Hotspot
8 min read
Lassa fever Indication Strategy Report 2026: Lassa GP, Trials and Deals
23 July 2026
2026 Lassa fever strategy: epidemiology, Lassa GP biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Ebola virus disease Indication Strategy Report 2026: Ebola GP, Trials and Deals
23 July 2026
2026 Ebola virus disease strategy: epidemiology, Ebola GP biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Marburg virus disease Indication Strategy Report 2026: Marburg GP, Trials and Deals
23 July 2026
2026 Marburg virus disease strategy: epidemiology, Marburg GP biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Nipah virus disease Indication Strategy Report 2026: Nipah G protein, Trials and Deals
23 July 2026
2026 Nipah virus disease strategy: epidemiology, Nipah G protein biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Nephrogenic diabetes insipidus Indication Strategy Report 2026: V2R, Trials and Deals
23 July 2026
2026 Nephrogenic diabetes insipidus strategy: epidemiology, V2R biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Distal renal tubular acidosis Indication Strategy Report 2026: AE1, Trials and Deals
23 July 2026
2026 Distal renal tubular acidosis strategy: epidemiology, AE1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Liddle syndrome Indication Strategy Report 2026: ENaC, Trials and Deals
23 July 2026
2026 Liddle syndrome strategy: epidemiology, ENaC biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Gitelman syndrome Indication Strategy Report 2026: NCC, Trials and Deals
23 July 2026
2026 Gitelman syndrome strategy: epidemiology, NCC biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Bartter syndrome Indication Strategy Report 2026: NKCC2, Trials and Deals
23 July 2026
2026 Bartter syndrome strategy: epidemiology, NKCC2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Dent disease Indication Strategy Report 2026: CLCN5, Trials and Deals
23 July 2026
2026 Dent disease strategy: epidemiology, CLCN5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Autosomal dominant tubulointerstitial kidney disease Indication Strategy Report 2026: UMOD, Trials and Deals
23 July 2026
2026 Autosomal dominant tubulointerstitial kidney disease strategy: epidemiology, UMOD biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Medullary sponge kidney Indication Strategy Report 2026: CaSR, Trials and Deals
23 July 2026
2026 Medullary sponge kidney strategy: epidemiology, CaSR biology, clinical competition, recent deals, unmet need and market attractiveness.